Hairy cell leukemia treated with cladribine
BACKGROUND: Hairy cell leukaemia is a chronic B-cell disorder that follows an indolent course. Cladribine has in the last decade emerged as the drug of choice for treating hairy cell leukaemia.
MATERIAL: We report on the long-term follow-up of 26 patients treated from January 1992 to June 1993 with cladribine administered subcutaneously.
RESULTS: 25 patients were evaluable for response. 21 patients (84%) achieved complete remission, three patients (12%) achieved partial remission, and one patient had no response. At a median follow-up of 6.8 years, 24 patients (92%) were still alive. One patient died from infections four months after treatment, while the other patient died from a malignant melanoma 4.4 years after treatment. Relapse assessed by flow cytometry was diagnosed in 95% of the patients. 38% of those in complete and 67% of those in partial remission were treated by a second course of cladribine during the follow-up. Retreatment led to normalisation of peripheral blood count in all patients.
INTERPRETATION: Cladribine is not a curative treatment in hairy cell leukaemia, but it induces long lasting remission.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2002 |
|---|---|
| Erschienen: |
2002 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:122 |
|---|---|
| Enthalten in: |
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke - 122(2002), 11 vom: 30. Apr., Seite 1094-7 |
| Sprache: |
Norwegisch |
|---|
| Weiterer Titel: |
Hårcelleleukemi behandlet med cladribin |
|---|
| Beteiligte Personen: |
Ghanima, Waleed [VerfasserIn] |
|---|
| Themen: |
47M74X9YT5 |
|---|
| Anmerkungen: |
Date Completed 13.08.2002 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM119174243 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM119174243 | ||
| 003 | DE-627 | ||
| 005 | 20231222184204.0 | ||
| 007 | tu | ||
| 008 | 231222s2002 xx ||||| 00| ||nor c | ||
| 028 | 5 | 2 | |a pubmed24n0397.xml |
| 035 | |a (DE-627)NLM119174243 | ||
| 035 | |a (NLM)12043051 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a nor | ||
| 100 | 1 | |a Ghanima, Waleed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hairy cell leukemia treated with cladribine |
| 246 | 3 | 3 | |a Hårcelleleukemi behandlet med cladribin |
| 264 | 1 | |c 2002 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 13.08.2002 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Hairy cell leukaemia is a chronic B-cell disorder that follows an indolent course. Cladribine has in the last decade emerged as the drug of choice for treating hairy cell leukaemia | ||
| 520 | |a MATERIAL: We report on the long-term follow-up of 26 patients treated from January 1992 to June 1993 with cladribine administered subcutaneously | ||
| 520 | |a RESULTS: 25 patients were evaluable for response. 21 patients (84%) achieved complete remission, three patients (12%) achieved partial remission, and one patient had no response. At a median follow-up of 6.8 years, 24 patients (92%) were still alive. One patient died from infections four months after treatment, while the other patient died from a malignant melanoma 4.4 years after treatment. Relapse assessed by flow cytometry was diagnosed in 95% of the patients. 38% of those in complete and 67% of those in partial remission were treated by a second course of cladribine during the follow-up. Retreatment led to normalisation of peripheral blood count in all patients | ||
| 520 | |a INTERPRETATION: Cladribine is not a curative treatment in hairy cell leukaemia, but it induces long lasting remission | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Cladribine |2 NLM | |
| 650 | 7 | |a 47M74X9YT5 |2 NLM | |
| 700 | 1 | |a Heldal, Dag |e verfasserin |4 aut | |
| 700 | 1 | |a Tjønnfjord, Geir E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke |d 1946 |g 122(2002), 11 vom: 30. Apr., Seite 1094-7 |w (DE-627)NLM00004475X |x 0807-7096 |7 nnns |
| 773 | 1 | 8 | |g volume:122 |g year:2002 |g number:11 |g day:30 |g month:04 |g pages:1094-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 122 |j 2002 |e 11 |b 30 |c 04 |h 1094-7 | ||